Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06054971 · ClinicalTrials.gov registry record
NSAA NON-Interventional Study Protocol
A clinical trial of Duchenne Muscular Dystrophy, sponsored by Red Nucleus Enterprise Solutions.
- Completed
- Registry status
- 31
- Enrollment target
- 1
- Study location
NCT06054971: Completed study of Duchenne Muscular Dystrophy, sponsored by Red Nucleus Enterprise Solutions.
NCT06054971 is a study of Duchenne Muscular Dystrophy that has completed, run by Red Nucleus Enterprise Solutions. The registered enrollment target is 31 participants, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06054971, a study of Duchenne Muscular Dystrophy, has completed, sponsored by Red Nucleus Enterprise Solutions.
- COMPLETED
- Registry status
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this non-interventional study is to evaluate the feasibility of remotely administering the North Star Ambulatory Assessment (NSAA) to participants with Duchenne muscular dystrophy (DMD). The iTakeControl (iTC) software platform will be utilized to remotely administer and score the NSAAs.
Conditions Studied
Interventions
- OTHER Remote Administration of NSAA
Study Locations (1)
Pennsylvania
- Red Nucleus Solutions - Malvern
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2023-10-02 |
| Est. Completion | 2025-03-13 |
What the finished NCT06054971 record still lists
NCT06054971 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which Remote Administration of NSAA is the first listed.
NCT06054971 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06054971 about?
NCT06054971 is a clinical study titled "NSAA NON-Interventional Study Protocol". The purpose of this non-interventional study is to evaluate the feasibility of remotely administering the North Star Ambulatory Assessment (NSAA) to participants with Duchenne muscular dystrophy (DMD). The iTakeControl (iTC) software platform will be utilized to remotely administer and score the NSA...
What is the current status of trial NCT06054971?
This trial is currently completed. The enrollment target is 31 participants. The study started on 2023-10-02. Estimated completion is 2025-03-13.
What conditions does trial NCT06054971 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy.
What interventions are being tested in trial NCT06054971?
The interventions under investigation include: Remote Administration of NSAA (OTHER).
Who is sponsoring clinical trial NCT06054971?
This trial is sponsored by Red Nucleus Enterprise Solutions, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06054971 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Duchenne Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06054971's enrollment target sits among peer trials
31 32nd of 48 higher than 17 of 48 other Duchenne Muscular Dystrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Duchenne Muscular Dystrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
RECRUITING · Phase 1
-
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
RECRUITING · Phase 2
-
Once Weekly Infant Corticosteroid Trial for DMD
RECRUITING · Phase 4
-
The Duchenne Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI